PRE-PEN Drug Profile

« Back to Dashboard

Summary for Tradename: PRE-PEN

High Confidence Patents:	0
Applicants:	1
BLAs:	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PRE-PEN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PRE-PEN Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PRE-PEN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Allerquest, Llc	PRE-PEN	benzylpenicilloyl polylysine	Injection	050114	8,263,125	2025-05-19	Patent claims search
Allerquest, Llc	PRE-PEN	benzylpenicilloyl polylysine	Injection	050114	8,268,352	2025-05-19	Patent claims search

PRE-PEN Market Dynamics, Patent Status, FDA Exclusivity, and Financial Trajectory

Last updated: October 30, 2026

PRE-PEN is a niche diagnostic biologic used to evaluate immediate hypersensitivity to penicillin. Its commercial value is driven by allergy testing volume, hospital antimicrobial-stewardship programs, and the need to remove inaccurate penicillin-allergy labels. The product has limited direct competition in the U.S. because it is the principal commercially available major determinant reagent for penicillin skin testing. Its long-term financial trajectory is likely stable rather than high-growth: market expansion depends on broader testing adoption, while low unit demand and limited reimbursement scale constrain revenue.

What is PRE-PEN and what does it diagnose?

PRE-PEN contains benzylpenicilloyl polylysine, also called penicilloyl-polylysine. It is administered by intradermal or skin-prick testing as part of an evaluation for immediate hypersensitivity to penicillin.

The product detects sensitivity to the major antigenic determinant formed when penicillin binds to proteins. A complete evaluation may also use penicillin G and, depending on the protocol, minor determinant reagents. PRE-PEN does not replace clinical history, supervised drug challenge, or specialist assessment.

Product attribute	PRE-PEN status
Active diagnostic component	Benzylpenicilloyl polylysine
Therapeutic category	Allergy diagnostic agent
Primary use	Penicillin skin testing
Dosage form	Injectable diagnostic solution
Administration	Skin-prick and intradermal testing
U.S. manufacturer	ALK-Abelló, Inc.
FDA pathway	Approved prescription diagnostic product
Main customer groups	Allergy practices, hospitals, academic medical centers
Direct U.S. substitute	Limited; testing protocols may use penicillin G and oral challenge
Revenue disclosure	Not separately reported publicly

FDA labeling identifies PRE-PEN as a diagnostic aid for patients with a history suggesting immediate hypersensitivity to penicillin. The product is not a treatment for infection or an allergy desensitization product (U.S. Food and Drug Administration [FDA], n.d.-a).

What is the FDA regulatory status of PRE-PEN?

PRE-PEN is an FDA-approved prescription diagnostic product. It is regulated as a drug rather than as a conventional laboratory-developed test. Its clinical use is tied to physician-supervised allergy assessment.

The regulatory value of PRE-PEN is based on the absence of a broadly available FDA-approved commercial replacement for the penicilloyl major determinant in U.S. practice. Penicillin-allergy evaluation can be conducted through different protocols, but the major determinant remains important for patients with histories suggestive of immediate reactions.

The product does not benefit from biologic reference-product exclusivity in the same manner as a therapeutic monoclonal antibody. It is also not a conventional biologic with a biosimilar pathway. Any competing product would likely require its own FDA approval as a diagnostic drug, although alternative testing strategies can compete at the clinical-service level.

Does PRE-PEN have FDA exclusivity?

PRE-PEN’s original regulatory exclusivity has expired. The product’s commercial protection now depends primarily on manufacturing capability, regulatory know-how, clinical familiarity, distribution, and the limited size of the market.

No meaningful new-drug exclusivity period is expected to restrict competitors. Any current market advantage is operational rather than based on remaining statutory exclusivity.

What patents protect PRE-PEN?

PRE-PEN’s foundational composition and use patents would have expired after several decades of commercial availability. No active, commercially significant Orange Book patent barrier is generally associated with the product.

Protection category	Current commercial relevance
Original composition patents	Expired
Original method-of-use patents	Expired
FDA exclusivity	Expired
Orange Book patent barrier	No material current barrier identified
Manufacturing know-how	Potentially relevant
Supplier and quality systems	Commercially relevant
Proprietary clinical protocols	Usually not product exclusivity

The absence of a current patent barrier does not mean that a competitor could immediately enter. A new manufacturer would need to establish a compliant source of the active diagnostic component, validate manufacturing controls, demonstrate product quality, obtain FDA approval, and build distribution into allergy and hospital channels.

How strong is the PRE-PEN patent estate?

The patent estate is weak as a current exclusionary asset because the product has been marketed for decades and its core intellectual property is old. The more important barriers are regulatory and manufacturing barriers.

The product’s defensibility comes from:

1. Regulatory history and physician familiarity.
2. A specialized active ingredient and supply chain.
3. Small market size relative to the cost of a new FDA submission.
4. Clinical integration into penicillin-allergy testing protocols.
5. Limited commercial incentive for multiple suppliers to enter.

These factors can preserve a niche franchise even when patent protection has ended.

When does PRE-PEN lose exclusivity?

PRE-PEN’s statutory and patent exclusivity has already expired. There is no major future loss-of-exclusivity event comparable to the patent cliff for a blockbuster therapeutic drug.

The relevant commercial question is whether a competitor can establish an FDA-approved alternative or whether hospitals shift toward oral challenge protocols and other allergy-testing methods.

Are there Paragraph IV challenges to PRE-PEN?

No major publicly visible Paragraph IV litigation campaign is associated with PRE-PEN. The product does not appear to be a current target of the type of generic litigation seen for high-revenue drugs with substantial patent protection.

A future abbreviated or hybrid application could still create regulatory competition, but the small addressable market reduces the financial incentive for a conventional generic launch.

What is the Orange Book status of PRE-PEN?

PRE-PEN’s value in the Orange Book is primarily as an FDA-approved diagnostic product rather than as a patent-protected franchise. The absence of a material listed-patent barrier reduces litigation risk but also leaves the product exposed to regulatory substitution if another sponsor enters.

Orange Book status should be evaluated together with:

• The current FDA approval record.
• Product availability and shortage history.
• Any approved supplements or manufacturing-site changes.
• National Drug Code listings.
• Reimbursement for the product and associated skin-testing services.

For commercial diligence, the relevant distinction is between product approval and patent exclusivity. PRE-PEN can remain commercially useful after patent expiry because physicians need a validated reagent, but it cannot rely on patents to prevent competition.

What drives demand for PRE-PEN?

Demand is linked to the number of patients carrying a penicillin-allergy label and the willingness of clinicians to test those patients.

About 10% of U.S. patients report a penicillin allergy, but most do not have a current clinically significant allergy. The CDC has stated that penicillin allergy evaluations can improve antibiotic selection and reduce use of broader-spectrum alternatives (Centers for Disease Control and Prevention, n.d.).

Key demand drivers include:

Penicillin-allergy delabeling

Patients incorrectly labeled as allergic may receive more expensive or less effective alternatives, including fluoroquinolones, clindamycin, vancomycin, or broad-spectrum cephalosporins. Allergy testing can allow use of first-line beta-lactam therapy.

Hospital antimicrobial stewardship

Hospitals have a financial and clinical incentive to reduce unnecessary broad-spectrum antibiotic use. Penicillin-allergy testing can support stewardship programs, particularly in surgery, infectious disease, hematology, oncology, and obstetrics.

Surgical prophylaxis

A penicillin-allergy label can lead to substitution away from cefazolin, the preferred prophylactic agent for many procedures. Testing programs can improve access to preferred prophylaxis.

Increasing allergy-clinic capacity

Growth in allergy practices, outpatient procedure centers, and pharmacist-supported delabeling programs can increase testing volume. Adoption remains limited by specialist availability, staffing, protocols, and reimbursement.

What competitive threats affect PRE-PEN?

PRE-PEN faces more clinical substitution risk than direct product competition.

Competitive option	Impact on PRE-PEN
Penicillin G skin testing	Can complement or partially substitute for PRE-PEN
Supervised oral amoxicillin challenge	Important alternative for low-risk patients
Direct oral challenge without skin testing	Reduces reagent demand in selected patients
Hospital allergy-delabeling programs	Can increase total testing demand
Laboratory-developed testing methods	Potential long-term regulatory and clinical substitute
New FDA-approved determinant reagents	Direct competitive threat
No testing or continued allergy-label avoidance	Demand-negative outcome

Clinical guidelines increasingly distinguish low-risk from high-risk allergy histories. Low-risk patients may proceed directly to an oral challenge under an appropriate protocol, reducing the need for skin testing. Patients with anaphylaxis, immediate urticaria, or other high-risk histories are more likely to require skin testing before challenge.

This creates a two-part market. High-risk patients support PRE-PEN demand, while low-risk delabeling pathways can reduce reagent use per patient.

What are the manufacturing and intellectual-property barriers?

The principal barriers are not patents. They are quality, reproducibility, and regulatory compliance.

A new supplier would need to manage:

• Consistent production of benzylpenicilloyl polylysine.
• Control of potency and impurity profiles.
• Sterility and injectable-product requirements.
• Stability data and container-closure compatibility.
• Validated skin-test performance.
• FDA submission requirements.
• Reliable production at low annual volume.
• Distribution to a fragmented specialist market.

The low-volume economics are important. A potential entrant must recover development and compliance costs from a product used in a specialized diagnostic market. If annual demand is modest, a single incumbent can remain commercially viable even without patent protection.

What is the financial trajectory for PRE-PEN?

ALK-Abelló does not publicly report PRE-PEN revenue as a separate product line. Its financial trajectory therefore cannot be measured through audited product-level sales, operating margin, or prescription data.

The commercial profile is best characterized as a mature, low-volume specialty diagnostic product:

Financial factor	Expected effect
Large patient population with penicillin labels	Expands theoretical market
Limited allergy-testing capacity	Restricts realized demand
Antimicrobial-stewardship adoption	Supports gradual growth
Oral challenge protocols	Reduces testing intensity for low-risk patients
Lack of product-level disclosure	Limits revenue visibility
Limited direct competition	Supports retention
Reimbursement pressure	Constrains pricing power
Specialized manufacturing	Raises replacement and entry barriers

Revenue growth is more likely to come from increased testing penetration than from price increases. Hospitals may expand testing programs when antibiotic stewardship produces measurable savings, but those programs require staffing and operating investment.

PRE-PEN is unlikely to become a large pharmaceutical revenue contributor without a major expansion in penicillin-allergy evaluation. Its strategic value may exceed its direct revenue value because it supports a broader allergy-testing portfolio and reinforces ALK-Abelló’s position in diagnostic immunology.

What generic launch scenarios exist for PRE-PEN?

Three scenarios are commercially plausible.

Scenario 1: No direct generic entry

The incumbent remains the only widely recognized commercial source. Demand grows slowly through hospital delabeling and allergy-clinic adoption.

Scenario 2: FDA-approved competing reagent

A second supplier enters with an approved major determinant product. Price competition increases, but physician adoption depends on clinical confidence, supply reliability, and reimbursement.

Scenario 3: Clinical substitution

Direct oral challenges and protocol simplification reduce skin-testing volume. PRE-PEN remains important for high-risk patients but loses volume among low-risk cases.

The third scenario is the most important medium-term risk because it does not require a patent challenge or competing product approval.

What patent litigation and settlement agreements affect PRE-PEN?

No material patent litigation or settlement agreement is publicly associated with PRE-PEN’s current commercial position. The product’s mature patent profile makes Paragraph IV litigation unlikely unless a new entrant seeks approval under a pathway that references a current regulatory filing and encounters a newly asserted patent.

The principal legal risks are more likely to involve product liability, labeling, supply obligations, or regulatory compliance than patent infringement.

How does PRE-PEN compare with other allergy-testing products?

Attribute	PRE-PEN	Penicillin G testing	Oral amoxicillin challenge
Role	Major determinant reagent	Complementary skin-test reagent	Functional tolerance assessment
Product dependence	Requires approved injectable reagent	Uses penicillin preparation	Requires supervised administration
Best fit	Higher-risk histories	Combined evaluation	Selected low-risk patients
Revenue model	Product plus testing procedure	Product plus testing procedure	Procedure and observation time
Direct patent exposure	Low	Low	Protocol-based
Main limitation	Specialist testing capacity	Incomplete determinant coverage alone	Not suitable for all histories

PRE-PEN is strongest where clinicians need structured skin testing before challenge. Oral challenge is more efficient for selected low-risk patients but is not a universal replacement.

Key Takeaways

• PRE-PEN is an FDA-approved diagnostic product containing benzylpenicilloyl polylysine.
• Its patent and statutory exclusivity have expired.
• No major current Orange Book patent barrier or Paragraph IV litigation campaign defines the product.
• The product’s commercial protection comes from regulatory history, manufacturing expertise, limited market size, and physician familiarity.
• Demand is supported by penicillin-allergy delabeling, antimicrobial stewardship, and surgical prophylaxis programs.
• Direct oral challenges create the main volume risk, especially for low-risk patients.
• ALK-Abelló does not publicly disclose PRE-PEN-specific revenue.
• The financial profile is that of a mature niche diagnostic product with stable-to-modest growth potential rather than a high-growth pharmaceutical asset.
• A competing FDA-approved reagent could create price pressure, but the small market may discourage entry.
• The main commercial diligence issues are supply continuity, reimbursement, testing volume, and clinical adoption.

FAQs

Is PRE-PEN a biologic drug or a diagnostic product?

PRE-PEN is an FDA-approved injectable diagnostic product used in penicillin-allergy skin testing. It is not a therapeutic biologic such as a monoclonal antibody and does not have a conventional biosimilar market.

Can PRE-PEN be replaced by an amoxicillin challenge?

For selected low-risk patients, clinicians may use a supervised oral amoxicillin challenge without skin testing. Higher-risk patients may still require skin testing with PRE-PEN and other reagents before challenge.

Does PRE-PEN have an unexpired patent?

No material unexpired foundational patent is generally associated with PRE-PEN’s current commercial position. Its principal protection is regulatory and operational rather than patent-based.

Who manufactures PRE-PEN?

PRE-PEN is associated with ALK-Abelló, a specialty pharmaceutical company focused on allergy diagnostics and immunotherapy products.

Is PRE-PEN revenue publicly disclosed?

No separate audited revenue figure for PRE-PEN is generally disclosed in public company reporting. Financial analysis must therefore rely on market structure, testing utilization, reimbursement, and competitive-entry indicators.

References

Centers for Disease Control and Prevention. (n.d.). Penicillin allergy. https://www.cdc.gov/antibiotic-use/hcp/clinical-care/penicillin-allergy.html

U.S. Food and Drug Administration. (n.d.-a). PRE-PEN: Benzylpenicilloyl polylysine injection prescribing information. https://www.accessdata.fda.gov/

U.S. Food and Drug Administration. (n.d.-b). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

ALK-Abelló. (n.d.). Annual reports and company information. https://www.alk-abello.com/